ARCHIVES

Ethicists dispute von Eschenbach’s claim that his NCI-FDA conflicts are managed. NCI-FDA chief appears to cite Klausner-era “in-box rule.”

This article is from The Cancer Letter archive.

Vol. 31 No. 46 | December 16, 2005

Download PDF Visit The Full Archive

Related Articles

Professional Societies: ASCO opposes FDA On Stem Cell Transplant Regs

May 16, 1997

Board Defers core Guideline changes, Asks Subcommittee For Alternate Plans

November 18, 1977

In Brief: Columbia University Double Lab Space; GM Cancer Awards to Suit, Folkman, Nurse

June 6, 1997

Partnership Points to New Path Forward For Drug Approval and Clinical Research

June 20, 2014

In Brief: Travel Grants available For 14th International Congress; NIH Seeks Nurses For Study Sections

November 22, 1985

Guideline Revisions or Outstanding Investigator Grant Still Controversial

December 9, 1983